. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: J Surg Res. 2013 May 11;184(1):10.1016/j.jss.2013.04.042. doi: 10.1016/j.jss.2013.04.042

Table.

Patient demographics, receptor status, and stage as a function of response to neoadjuvant chemotherapy.

	Partial response	pCR	P value
Patients	19	4
Age	50.7 ± 11.5	40.0 ± 10.7	0.14
ER positive	16 (84%)	1 (25%)	0.04
Her2 positive	3 (16%)	2 (50%)	0.19
Triple negative	2 (11%)	1 (25%)	0.45
Stage II	9 (47%)	2 (50%)	1.0
Stage III	10 (53%)	2 (50%)	1.0
Adriamycin-based chemotherapy	16 (84%)	3 (75%)	1.0